Ian has more than 25 years of experience in the pharmaceutical industry, gained through senior positions in sales, marketing, business development & licensing in both multinational companies and biotech. Through Atebion BDS, he assists spin-outs, BioTech and Major Pharmaceutical Companies in their strategic investment decisions.
Read More →
Luke assists and supports Atebion BDS in matters requiring commercial legal expertise. He is Managing Director of Evetts Legal, a boutique law firm specialising in providing legal support in the pharmaceutical sector.
Read More →
Dave Simpson PhD has spent over 15 years’ in the biotherapeutics industry developing and commercialising biologics with Cobra Biologics, Eden Biodesign and Actavis (now Allergan) and is currently the CEO of Glythera Ltd, an Antibody Drug Conjugate development company.
Read More →
Tim Dempsey assists Atebion BDS in investor-related projects, whether this relates to defining investor strategy, brokering investor / VC meetings for Investment Rounds, providing company valuations or for the general support of investment decisions.
Read More →
